Novo Nordisk (NVO) shares stumble after the results of the drugmaker's weight loss drug trial showed that patients using the drug dropped only around 15% of their weight, compared to the 25% ...
U.S. shares in Novo Nordisk, a leading maker of anti-obesity drugs, were down roughly 4% Wednesday afternoon. But shares in Eli Lilly, the other major weight-loss player, were little changed.
Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results